Prospective study of an orally-active ghrelin receptor agonist in patients with unresectable pancreatic cancer and cachexia
Not Applicable
Recruiting
- Conditions
- pancreatic cancer
- Registration Number
- JPRN-UMIN000044724
- Lead Sponsor
- Graduate School of Medicine, The University of Tokyo
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
Not provided
Exclusion Criteria
1. Judgement by doctors 2. Off label use for selective ghrelin receptor agonist
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in the body weight from the baseline over the 12-week treatment period
- Secondary Outcome Measures
Name Time Method 1. the changes in visceral fat and subcutaneous fat 2. adverse events of selective agonist of the ghrelin receptor 3. treatment periods of selective agonist of the ghrelin receptor 4. Progression free survival of chemotherapy 5. Overall survival of chemotherapy 6. Tumor response rate 7. Disease control rate 8. Adverse events of chemotherapy 9. QOL assessment